Day One Bio files 10-K/A amendment
Ticker: DAWN · Form: 10-K/A · Filed: Mar 6, 2025 · CIK: 1845337
Sentiment: neutral
Topics: amendment, annual-report, pharmaceuticals, financials
TL;DR
Day One Bio filed an amended 10-K for 2024, updating financials and disclosures.
AI Summary
Day One Biopharmaceuticals, Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ending December 31, 2024. The filing, submitted on March 6, 2025, provides updated information and disclosures. Key financial items mentioned include retained earnings and research and development expenses, with specific references to a Merck License Agreement and employee stock plans.
Why It Matters
This amendment to the annual report provides updated financial and operational disclosures for Day One Biopharmaceuticals, Inc., which could impact investor understanding of the company's performance and future outlook.
Risk Assessment
Risk Level: low — This filing is an amendment to an annual report, typically providing clarifications or updates rather than introducing new, significant risks.
Key Numbers
- 2024-12-31 — Fiscal Year End (The period covered by the amended annual report.)
- 2025-03-06 — Filing Date (The date the 10-K/A amendment was submitted to the SEC.)
Key Players & Entities
- Day One Biopharmaceuticals, Inc. (company) — Filer of the 10-K/A
- Merck License Agreement (company) — Mentioned in relation to R&D expenses
- 2000 Sierra Point Parkway, Suite 501, Brisbane, CA 94005 (address) — Company's business and mailing address
- 2024-12-31 (date) — Fiscal year end
- 2025-03-06 (date) — Filing date of the amendment
FAQ
What specific information was updated or clarified in this 10-K/A filing?
The filing is an amendment to the 10-K for the period ending December 31, 2024, and includes updated financial information and disclosures, though the specific nature of the updates requires a deeper review of the document's content beyond the provided header information.
What is the primary business of Day One Biopharmaceuticals, Inc.?
Day One Biopharmaceuticals, Inc. operates in the Pharmaceutical Preparations industry, as indicated by its SIC code [2834].
When was the company formerly known as Day One Biopharmaceuticals Holding Co LLC?
The company's name changed from Day One Biopharmaceuticals Holding Co LLC on February 9, 2021.
What are some of the financial items mentioned in relation to the fiscal year 2024?
For the fiscal year 2024, the filing references items such as retained earnings, research and development expenses, accumulated other comprehensive income, and employee stock options and restricted stock units.
Does the filing mention any significant agreements or partnerships?
Yes, the filing specifically mentions the 'Merck License Agreement' in the context of research and development expenses for the period January 1, 2024, to December 31, 2024.
Filing Details
This Form 10-K/A (Form 10-K/A) was filed with the SEC on March 6, 2025 regarding Day One Biopharmaceuticals, Inc. (DAWN).